Patents and Intellectual Property

Patents (six issued in U.S., one in Japan, two in Europe, two in Canada)

  • Initial U.S. patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued with method of treatment claims for RA, juvenile RA, and systemic lupus erythematosus (SLE)
  • U.S. continuation patents expanding use, issued with method of treatment claims for:
    • ITP or autoimmune TP in 2008
    • Reducing an acute inflammatory response or inflammation in 2010
    • Psoriasis and scleroderma in 2012
    • MS in 2013
    • Type 1 Diabetes in 2016
  • Japanese patent issued with composition claims treating psoriasis, scleroderma, Crohn’s Disease, myasthenia gravis, ulcerative colitis, psoriatic arthritis, and pemphigus vulgaris.
  • European patents issued with composition claims relating to numerous autoimmune diseases (RA, ITP, juvenile RA, psoriasis, myasthenia gravis) and dosage expansion; Notice of intention to grant received for 3rd patent for treatment of inflammation.
  • Canadian patents issued Dec. 2016 with method of treatment claims relating to RA and Lupus. Hong Kong request for registration filed Dec. 2016.
  • Additional patent applications pending in Europe and Japan.

Other Intellectual Property

  • Considerable know-how in the manufacture and QA of highly purified SpA expected to remain trade secret